Introduction
Today advances in the design of modern drugs rely on an understanding of their mechanism of action. Positron Emission Tomography (PET) has proven to be an important imaging tool for diagnosis in oncology, cardiology and neurology and more recently in personalised medicine (Roach, M. et al., 2011; Smith, S.V., 2005) . Its exquisite sensitivity (<10 -9 M) has made it a valuable tool in the screening and risk assessment of new agents in drug development programs (Cropley, V.L. et al., 2006; Gomes, C.M.F. et al., 2011; Gregoire, V. et al., 2007; Lancelot, S. & Zimmer, L., 2010; Langer, A.2010; Lonsdale, M.N. & Beyer, T., 2010; Roach, M. et al., 2011; Seam, P. et al., 2007; Truong, M.T. et al., 2011; Vyas, N.S. et al., 2011; Wahl, R.L. et al., 2009) . It has been mainly focused on the use of the classical short lived PET isotopes, 11 C and 18 F, in the evaluation of small molecular weight molecules. PET contributions to the molecular imaging and drug development fields however would be significantly enhanced if longer lived PET radioisotopes were readily available. Generally metal PET radioisotopes are better suited for labelling larger molecular agents such as peptides, proteins and particles. This chapter will review a range of metal PET radioisotopes under development, assess their physical characteristics and suitability for PET imaging.
How does PET work?
The high sensitivity of PET is related to its mode of detection. The positron ( + ) which is emitted from the PET isotope must lose sufficient energy (to <100 eV) so it is able to attach to an electron and form the neutral, unstable positronium. The positronium annihilates rapidly (within less than 150 picoseconds (ps)) to give off two 511 keV gammas simultaneously, in opposite directions. If the two coincident gammas are detected by the circumferentially arranged detectors within a fixed time period, it is assumed that they arise from the same radioactive source (see Figure 1 ). This co-registration of the gamma signals allows one to determine the location and concentration of the PET probe in the body (Lonsdale, M.N. &Beyer, 2010 T.; Smith, S.V., 2005) .
PET Imaging
The quality of information gained by PET imaging is governed by the spatial resolution and sensitivity of PET to the radioisotope used. While the sensitivity and flexibility of PET is (Baker, M., 2010; Pimlott, S.L. &Sutherland, A., 2011; Smith, S.V., 2005) 
Human PET cameras
The first PET camera was developed in the 1950s and by the 90s they were well established imaging tools. Its detectors (up to 32 thousand) are arranged in a ring around the subject of interest. To obtain an image, the subject containing the PET agent is moved within the field of view of the detectors. The radioactivity present in the region of interest is measured and the data is processed to generate a 3 D image. The radial distribution of the detectors can be varied. For human whole body and brain imaging PET diameters are approximately 70-87 cm and 40-50 cm, respectively (Lee , J.S., 2010; Moses, W.W. et al., 1997) . The further the detectors are placed apart the more likely the gamma signal will deviate from 180 o C (i.e.
Energies 20-30 MeV
These cyclotrons are used to produce both SPECT (e.g. 67 Ga, 201 Tl, 111 In and 123 I) and PET radioisotopes. Gas, liquid and solid target systems are available. Beam currents are less than 50 A for gas and liquid, and up to 250 A for solid target systems. These cyclotrons are generally dedicated facilities, requiring highly skilled staff to maintain them. These production facilities can be located a substantial distance (i.e. different continents) from the nuclear medicine department.
Energy 30-70 MeV
High intensity and high energy cyclotrons are generally deployed for the production of large quantities of radioisotopes for sale. Those operating in the higher energy range are commonly used for research purposes. The recently commissioned 70 MeV cyclotron at ARRONAX in France (Haddad, F. et al., 2008) will be used to produce radioisotopes for imaging and radiotherapy. 
Factors governing selection of a radioisotope
Historically, the criteria governing the selection of a PET radioisotope has been relatively simple and largely dominated by the availability, production yield and ability to image. Significant advances in design and stability of cyclotrons, cameras and data processing, has increased the potential range of PET radioisotopes. Today, the choice of PET radioisotopes is influenced by many factors (see Figure 2) . It is important to understand how they impact on the production and clinical setting as well as on patients when administered repeatedly.
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The half life of the PET radioisotope needs to match the biological half life of the carrier agent. For applications in diagnosis, this may simply be a radioisotope with a half life long enough to see the radiopharmaceutical accumulate in the diseased tissue and clear from blood. When imaging to determine prognosis of a patient (ability to respond to treatment) or assessing risk (therapeutic index) of an agent, the half life may need to be longer. For the latter, understanding uptake and clearance from all critical organs for a patient is important when determining its therapeutic index and or appropriate dose.
Image quality
The decay characteristics of the radioisotopes need to match the performance of the imaging camera. The resolution of PET remains dependent on three fundamental factors:
1. Non-collinearity of annihilating gammas (i.e. deviation from 180 o angle on emission of 511 keV signal) 2. Positron energy spectrum 3. Gamma emissions
Positrons
Non-collinearity can be reduced by bringing the detectors closer together. The higher the positron energies, the further they need to travel to lose enough energy to form a positronium, and this can cause images to blur (Pimlott, S.L. & Sutherland, A., 2011) . For human PET and particularly TOF-PET systems, the tolerance for the range of positron energies is higher than that of an animal PET camera. The spatial resolution of animal PET cameras is dependent on the maximum positron energy and its spectrum. Therefore in designing animal PET studies one needs to take into consideration the positron energy of the PET isotope.
Gamma emissions
Gamma emissions from the PET radioisotopes, of specified energies (and intensities), can interfere with the image quality, particularly those emitted within the PET discriminator window (ie. 350 and 700 keV). This leads to gamma coincidences that result in images of poor quality and flat unstructured background.
Dose
PET radioisotopes may decay via a number of pathways and give off x-rays, betas (i.e. electrons or positrons) and gammas. All of these emissions contribute to the total absorbed dose to the subject. From a production and imaging point of view it is the high intensity gamma emissions that cause concern for operators (i.e. production and animal handling staff) and applications in the clinical setting. Most PET facilities have been designed to handle 18 F and do not have sufficient shielding for high energy gammas Where the patient is concerned, the presence of high energy gammas prevents re-injection (such as that used in cardiology) due to accumulated radiation dose.
Cyclotron energy
Cyclotrons need to produce a beam of suitable particles at a desired energy and current for the preferred nuclear reaction. Inappropriate beam characteristics will prevent operators from producing sufficient quantities for clinic applications.
Nuclear reaction
Most PET radioisotopes are produced by bombarding a target material, which often is isotopically enriched. An enriched target is expensive (up to $1000s per target irradiation). As only a negligible (0.01%) portion of the target material is converted to the desired radioisotope, the target should be treated as an asset and recycled. Sometimes long lived gamma emitting radioisotopes can not be chemically removed. Their presence in the used target material can prevent its recycling in a timely manner. In such circumstances, a sizeable inventory of enriched target material needs to be purchased (e.g. >$250,000 US) to permit decay of contaminants prior to reuse.
Chemistry of the PET radioisotope
The ease, efficiency and cost of production of a PET radiopharmaceutical are affected by the chemistry of the radioisotope. The first aspect is the chemical separation of the PET radioisotope from the target material; this is more easily achieved if the target element is chemically different from the radioisotope. The separation process is generally conducted at the cyclotron site. The second aspect of PET radiopharmaceutical production is the incorporation of the PET radioisotope into the carrier agent. Such processes must be performed relatively quickly and preferably quantitatively in order to produce high specific activity products. The production of the radiopharmaceutical may require hot-cells and/or an automated system. This can add considerable cost to the process and prevent production of the desired PET radiopharmaceutical at the site of use.
Biological pathway
Each radioisotope needs to be stably secured to a carrier. However, if the radiolabelled carrier breaks down in vivo it is likely to release the radioisotope. As radioisotopes mimic their naturally occurring metal ions, they can be expected to excrete from the body using normal biological pathways. Hence in choosing the radioisotope, one needs to consider these pathways and their potential contribution to the radiation dose to patient. For example, copper excretes via the liver and can be recirculated with ceruloplasmin. All the copper isotopes, 60 Cu, 61 Cu, 62 Cu and 64 Cu are expected to behave in a similar manner. In contrast, 86 Y, like other lanthanides, will accumulate in bone while the biological pathway of 89 Zr is not known and therefore its behaviour is difficult to predict.
Metal PET radioisotopes
As mentioned previously the greatest potential for the PET radioisotopes is to provide diagnostic information on pathological processes and any changes to them, prior to anatomical changes. They have a significant role to play in both the screening of new diagnostic and therapeutic target agents in animal studies and in clinical trials. By radiolabelling the target agent, such as antibodies, the PET radiopharmaceuticals are used to determine the therapeutic index (distribution) of the antibody, the appropriate dose for the patient and also assist in selecting patients likely to respond to treatment. Radiometal isotopes can also be incorporated into a ligand or complexing agent and used to monitor various biological properties such as blood flow, hypoxia or glomerular filtration and or organ function (e.g. heart, kidney or liver) (Smith, S.V., 2004 and references within) . In this case, the design of the ligand and the resultant metal complex dictates the function of the PET radiopharmaceutical. If the ligand is bi-functional, one portion of the molecule will be responsible for complexing the metal radioisotope and the other will contain a reactive group (e.g. amino, carboxylic acid or isothiocyanate) that is responsible for coupling the metal complex to a target agent. For target agents with long biological half lives (i.e. hours and days) it is important to ensure the radiolabel is secured and stable in vivo until the target agent clears from the body. This ensures the PET signal in vivo is from the radiolabelled target agent and not the radioisotope in its ionic state or non-specifically bound to naturally occurring biological components. Furthermore, the half life of the radioisotope needs to be sufficiently long enough to monitor the localisation of its carrier to the disease site and attain a signal to noise ratio of at least 2 fold. 
Half life
The half lives of the radioisotopes presented in Table 3 vary from minutes to days. They may be classified into groups based on these half lives (see Figure 3) . The timeframes chosen take into consideration the time to purify the radioisotopes, its incorporation into a carrier agent and the packaging and transport of the resultant radiopharmaceutical across continents. The first class of radioisotope (t 1/2 = 1-60 mins) is generally used as surrogates for cations in vivo or incorporated into complexing agents. A number of the radioisotopes can be produced from a generator system (see Figure 4 ) making them more accessible to the wider PET community. Radioisotopes with longer half lives (hours to days) are best suited for studying the pharmacokinetics or dynamics of large molecules such as peptides, proteins and particles. Tc must be produced and used at or within a short distance from the cyclotron production centres. For example, 82 Rb + (t 1/2 = 1.3 min) is used in myocardial perfusion studies; it acts as a surrogate for K + . The very short half life of 82 Rb makes whole body imaging a challenge and precludes imaging after 10 mins. As a result activities of up to 1.5 GBq are administered to patients. Heart, kidney, lungs and pancreas receive an absorbed radiation dose of 5.1, 5.0, 2.8 and 2.4 mGy per MBq, respectively. This is significantly less than both 201 Tl and 99m Tc sestamibi SPECT agents (Senthamizhchelvan, S. et al., 2011) . The long half life of the parent 82 Sr (t 1/2 = 25.55 days) permits its transport throughout the world. The radioisotopes 60 Cu (t 1/2 = 23.7 min) and 62 Cu (t 1/2 = 9.6 min) have identical chemistry and can be interchanged depending on the carrier agent and the biological processes under investigation. The 62 Cu is produced from the parent 62 Zn (T 1/2 = 9.3 hour); its short half life requires the generator to be prepared daily.
The story with 52m Mn is more complex. It is produced from the positron-emitting parent 52 Fe (t 1/2 =8.3 hours) and then decays by positron emission to the long-lived daughter 52 Mn radioisotope (t 1/2 =5.591 days). While the 52 Mn emits a low energy positron its extraordinarily high energy gamma detracts from its use in PET imaging. A recent study, investigating the effect of the daughter 52m Mn on the 52 Fe PET image quality showed there was minor degradation, compared to 18 F. The positron energies for 60 Cu and 63 Zn are of similar intensity, the latter having comparatively less gamma emissions. It is surprising 63 Zn has not been reported in the literature more often. As Cu(II) and Zn(II) complex with similar chelating agents, there is potential to substitute 63 Zn for 60 Cu in emerging blood flow or hypoxia markers. Technetium-94m also has a short half life with a relatively high intensity positron emission. It decays to the positron emitter 94 Tc, which further decays giving off a large proportion of high energy gammas. The 94m Tc could potentially act as a surrogate for the SPECT 99m Tc agents but negligible improvement in imaging resolution is unlikely to compensate for the increased dose both to operator and subject. The application of radioisotopes ranging in half life from 1 hour to less than a day is varied. They are readily incorporated into chelators or carrier agents but their stability will be dependent on their respective coordination chemistry and redox chemistry. Generator produced 68 Ga (t 1/2 =1.1 hours) has been used to radiolabel a range of peptides including derivatives of octreotide (Gabriel, M. et al., 2007; Henze, M. et al., 2001 ) and arginineglycine-aspartate (RGD) (Li, Z.B. et al., 2008; Liu, Z.F. et al., 2009 
Gamma emissions -Safety
As mentioned previously, some gamma emissions from the PET isotopes can affect PET image quality, choice of shielding in production facilities and cause unnecessary absorbed dose to the subject. Shielding suitable for 18 F may not be sufficient to shield gammas with energies significantly greater than 500 keV (Madsen, M.T. et al., 2006) . Figure 5 illustrates a simple comparison of the relative energy and the intensities of gammas emitted from some of the radioisotopes given in Table 3 . The data clearly show that gammas generated from the decay of 60 Cu, 86 Y and 89 Zr are of significantly higher energies than that of 18 F; therefore these radioisotopes will require substantially more lead shielding for processing compared to that used for 18 F productions. Gammas in the range of 350 -700 keV (shaded green on image) from decay of 62 Zn and 86 Y will interfere with PET image quality, resulting in a reduced signal to noise ratio. In stark contrast, 62 Cu and 64 Cu have no significant gammas that will interfere with camera quality, nor do they require significant changes to current lead shielding used in PET facilities. Table 3 .
Radiation dose
As the energy and the probability of gamma emissions is specific for each radioisotope, they can be used to calculate the energy released per decay in the form of photons. The energy released per decay may be represented as MeV (Bq s) -1 , where 1 Bq = 1 decay per second.
Radiation dose received by an operator or patient is measured in Sievert, Sv. One Sv is equivalent to the energy absorbed per kilogram of mass (J/kg). In the case of the operator who is positioned at some distance from the radiation source, the dose received in Sv is a function of the intensity of the radiation, type of radiation, distance from the source and the time exposed to the source. It is convenient to discuss the dose rate in Sv/hr, so that the operator can determine the dose received for a specific time period. Figure 6 illustrates the dose rate per unit of radioactivity received by an operator at one metre distance from each unshielded PET radioisotope source. It shows the effect of high energy gammas can vary by 10-fold across the series of radioisotopes listed in Table 3 . These doses also need to be considered when dispensing the radiopharmaceutical and when injecting the subject (i.e. patient or animal) as they effectively become a radioactive source and shielding under these circumstances is not always practical. Fig. 6 . The dose rate per unit of radioactivity received by an operator at one metre from an unshielded source.
Shielding
The dose rate values in Figure 6 can be used to determine the shielding for the production, handling and storage of the PET isotopes. The shielding can then be adjusted to ensure the radiation exposure to the operator is kept within an acceptable level. The following relationship can be used to determine the shielding required:
where: I = intensity of the radiation after shielding, I 0 = intensity before shielding, t = thickness [cm] of shielding material (in this case lead), and
The linear attenuation coefficient takes into account the effect of photoelectric absorption, Compton collision, pair production and Rayleigh scattering. The relationship between linear attenuation and the energy coefficients for a range of photon energies is illustrated in Figure  7 (Hubbell, J.H., 1969) . The curve shows that for higher energy gammas travelling through lead, the attenuation is lower per unit of distance travelled. As a result, for the same intensity of radiation, a greater thickness of lead is required to shield an operator from higher energy photons than for lower energy photons. Photoelectric effect, Compton scattering and pair production can result in secondary photons. These photons have a finite probability of contributing to the total dose received by the operator. The extent to which these secondary photons contribute is described through the use of a build-up factor. For simplification this will be ignored here, but it should be noted that it is a multiplicative factor, that is, always greater than one. Further the multiplication factor is dependent on the energy of the incident photons, the atomic number of the shielding material and the thickness of the shielding. For further information regarding shielding calculations refer to Principles of Radiation Shielding (Chilton, A.B. et al., 1984) . To calculate the thickness of lead required to shield an operator for a quantity of radioactivity, the radiation is assumed to be at the highest energy gamma associated with the radioisotope decay. Further if we set the maximum permitted operator dose at 12 mSv per working year, the maximum dose rate for operator exposure is ~0.00625 mSv/hr where one year is equivalent to 48 wks at 40 hours/wk. To obtain the thickness of lead required to reduce the original intensity I 0 to the desired value I, equation (1) is rearranged to:
Assuming the source has 1Ci (37 GBq) of a PET radioisotope, the thickness of lead required to reduce the operator dose rate to 0.00625 mSv/hr may be calculated using (2). It is useful to combine the data of Figure 6 with Figure 7 and compare the dose rate per activity plotted with the relative thickness of required lead shielding to reduce the dose to specified levels in Figure 8 . In other words, the data show the relative thickness of shielding for the same amount of radioactivity for each PET isotope. For 60 Cu, a 5 fold greater thickness of lead shielding is required compared to an equivalent amount of 64 Cu radioactivity.
It is important however to note that the relative order of shielding required for each PET radioisotope in Figure 8 does not always correspond directly to the total dose rate discussed above. (Holland, J.P. et al., 2011) where the occupational exposure of staff increased when handling low amounts of activity (~1-25 mCi) of 86 Y and 89 Zr compared to significantly higher quantities of 18 F activity (~400-500 mCi). Furthermore, transport of these types of PET isotopes requires modification of shipment containers or significant reduction in the amount of activities to be shipped. The emission of high energy gammas from 86 Y and 89 Zr allow only ~1/162 and ~1/44 respectively of the maximum activity of 18 F to be transported in approved PET radioisotope shipment containers in the USA (Holland, J.P. et al., 2011) . Negligible change in shielding would be required for 64 Cu. 
Positron energy -Image quality
It is important to consider the energies of the positrons emitted from the PET radioisotopes when determining their application. Because the positron has to lose energy before it annihilates, it travels and interacts with tissue over a significant range (i.e. millimetres). As the density of the tissue can affect the rate at which the energy is lost from the positron, one may also expect the positron to travel further in lung tissue (because it is predominantly air). PET images in this region will be "blurred" and the spatial resolution will be poorer compared to other parts of the body where the density of tissue is higher. In contrast, for bone, which is considered electron rich and of dense composition, the PET image appears comparatively sharper.
For small animal PET cameras, PET radioisotopes emitting high energy positrons have a detrimental effect on image quality (Laforest, R. & Liu, X., 2008; Partridge, M. et al., 2006) . Laforest and Lui 2008 , reported that both the range the positron travels and the presence of cascades of gamma rays contributed to poor signal to noise ratios. In the same work, they compare phantoms containing either 60 Cu, 61 Cu, 64 Cu, 94m Tc or 86 Y and demonstrate how the positron energy can affect the image resolution. Improvement in spatial resolution of animal PET cameras using these radioisotopes can be achieved by an increase in imaging time and a reduction in the coincidence window limits to prevent contamination from other decay modes (Vandenberghe, S., 2006) . To do this the subject either needs to be injected with more radioactivity or kept in the field of view of the camera for longer periods of time. A more sophisticated approach to improve image quality is to develop image reconstruction algorithms that consider the nuclear decay and tomography response (Laforest, R. & Liu, X., 2008; Ruangma, A. et al., 2006) . Though the development of cyclotrons continues to flourish and in parallel the range of PET isotopes, understanding the track structure of positrons emitted is largely unresolved. Attempts to use Monte Carlo modelling to illustrate the tracking of positrons in tissues have been made by a number of groups. Work by Sanchez-Crespo et al. (Sanchez-Crespo, A. et al., 2004) has shown how the density of tissue can change the resolution of an image. But such modelling is unlikely to comprehensively predict the positron behaviour or its microdosimetry, until accurate measurements of the cross sections for the interaction of positrons and electrons with various biological molecules have been attained. Such data have the potential to improve the analysis of PET data and therefore the quality of PET images, as well as improve accuracy of absorbed radiation dose calculations. A closer examination of the PET radioisotopes considered in this chapter (see Table 3 ) shows that many of the isotopes can emit a number of positrons through the allowed decay paths. Understanding the kinetic energy spectra for each of these positrons is useful, as they affect the quality of the image to different degrees. In using equation 3 the positron energy spectra are calculated for the highest intensity positron per radioisotope in a similar manner to that reported by Le Loirec (Le Loirec, C. & Champion, C., 2007a) .
Where: E = total energy of the positron; Z = atomic number; a = fine structure constant; p = momentum of positron; E max = maximum allowed energy of positron; C = normalisation constant. The spectrum of the dominant positron emission for each radioisotope is illustrated in Figure 9 . The data demonstrate the range of positron energies per isotope and therefore the relative distance they are likely to travel in vivo. Of course, these values do not take into account the tissue density, but they can be used to give an indication of the relative quality of images to be obtained for each PET radioisotope. Fig. 9 . The spectrum of the dominant positron emission for each radioisotope Figure 10 (a) and (b) illustrate the relative intensity of kinetic energy spectra for  + decays (in colour dotted curves) of 61 Cu and 66 Ga respectively. These spectra do not take into account the relative intensity of each positron. Conversely the black curve is the result of the accumulated spectra taking into consideration the relative intensities of each. Figure 10a shows how a low energy positron (559 keV) can become insignificant when a high intensity of the higher energy positron (1215 keV) is present. A similar effect is evident for 66 Ga however the shape is significantly different and suggests the signal to noise ratio would be poorer. 
Production of metal positron emitting isotopes
There are many radioisotopes that can be produced with a cyclotron. The challenge in each case is to develop targetry (target material and loading system) that allows it to be kept stable in the beam of the accelerated particles and to remove the desired radioisotope quickly and efficiently. Unlike the well-known PET isotopes 11 C, 18 F and 15 N which are produced using gas or liquid based targetry, the metal radioisotopes listed in Table 3 are mostly generated from solid targets of metal based materials (e.g. metal element or metal oxide). The target can be placed within the cyclotron (under vacuum) or external to the cyclotron. In each case the target system needs to tolerate heat generated from the particle reactions. Depending on the energy and current of the beam (A or mA) the cooling systems can be quite elaborate.
As the number of nuclear reactions is potentially large, one needs to design the target so that the preferred nuclear reaction dominates. This may be achieved in a number of ways: a. The use of enriched isotopes for these types of reactions can add considerable cost to the production of a radioisotope. It is wise to treat the material as capital and recycle it for reuse. By using an enriched isotope for the target, one can also prevent or reduce the production of contaminating radioisotopes. If these contaminating radioisotopes have high gamma emissions or different half lives from the desired radioisotope, they can affect the shielding and timing of a production process, as well as delay the recycling of enriched target material. For example, 67 Ga is a SPECT agent produced by proton bombardment of enriched 68 Zn. By-products of this reaction are 66 Ga (t 1/2 =9.5 hr) and 65 Zn (t 1/2 =244 days), both of which produce high energy gammas. The former is often left to decay before the 67 Ga can be processed. Furthermore shielding of hot cells needs to be increased to reduce the dose to operators. The presence of the latter, 65 Zn, prevents recycling of the 68 Zn target material. Therefore, large inventories (~100g costing ~$250,000 US) of enriched 68 Zn is maintained so irradiated samples can be left to decay before recycling. The presence of a long lived radioisotope contaminant in the desired PET product can impact on its expiry time and use. Good target design is essential to ensure cost effectiveness and high quality product.
Generator produced PET isotopes
There is added complexity to the production and separation of short lived radioisotopes. For example, 82 Rb (T 1/2 = 1.3 min), 68 Ga (T 1/2 = 67.6 min) and 62 Cu (T 1/2 = 7.6 min) are all produced from their respective parent isotopes in a generator. These generators are then supplied to the PET facilities and milked periodically to resource the desired isotopes.
Nuclear reactions for PET radioisotopes
The type of nuclear reactions to produce a PET radioisotope can be quite varied. Table 4 summarises some of the more successful production routes for the PET radioisotopes, their nuclear reactions, useable energy range and the maximum cross section from the excitation function. The abundance of target element used for each reaction is also listed. , 1970; Hermanne, A. et al., 2000; Hille, M. et al., 1972; Ido, T. et al., 2002; International Atomic Energy Agency, 2009; Khandaker, M.U. et al., 2009; Sadeghi, M. et al., 2010; Sadeghi, M. et al., 2009; Szelecsényi, F. et al., 2001; Szelecsenyi, F. et al., 2006; Takacs, S. et al., 2003; Takacs, S. et al., 2007; Tarkanyi, F. et al., 2005) The cross sections for the production of 68 Ga via p and  bombardment of 68 Zn and 65 Cu targets respectively, are similar. The former production route would be preferred due to the wider availability of p producing cyclotrons. However it is important to note that 66 Ga which has a longer half life, can be produced via p bombardment of 66 Zn in the same energy region. As the natural abundances for 64 Zn, 66 Zn and 68 Zn are 48.6%, 27.9 % and 18.8 %, respectively, even small amounts of 64 Zn and 66 Zn present in enriched (>95%) 68 Zn will contribute to the production of contaminating isotopes. Generators for the production of 82 Rb (T 1/2 = 1.3 min) and 68 Ga (T 1/2 = 67.6 min) are commercially available. The long half lives of their respective parents, 82 Sr (T 1/2 = 25.3 days) and 68 Ge (T 1/2 = 270.8 days) means the generators have a life-time of months to almost a year. However the challenge in the production of these generators is that they must stand up to repeated milking over at least twice the lifetime of the generator to demonstrate that there is no breakdown of the column material or any leaching of contaminating long lived radioisotopes. The parent of 62 Cu, 62 Zn has a short half-life and needs to be prepared daily. This generator can be milked multiple times however the short half-life of the 62 Zn limits the lifetime of its use to less than a day. A comparison of the maximum cross section and the energy range suitable for the production of each PET isotope on a 30 MeV cyclotron is illustrated in Figure 11 . The green and blue icons represent p and d reactions at the maximum cross section. The associated error bar reflects the useable energy ranges (cross section >10 mb) for the respective reactions. Fig. 11 . Radioisotopes produced using protons and deuteron in the energy range 0-30 MeV.
In general, the production of radioisotopes via proton bombardment are more common across the energy ranges, as their high cross sections provide for higher yields. In contrast, nuclear reactions with deuterons are less common. This is not surprising as maintaining a stable beam of these particles at a high current is more difficult. Figure 11 have a very high probability. However the cost effectiveness of their production relies on the enrichment of their target material. The targets used to produce 89 Zr, 48 V, 63 Zn , 68 Ga and 68 Ge are of high (>60%) natural abundance (identified by the orange circles in Figure 11 ) and therefore will yield high quantities of these radioisotopes at comparatively reasonable cost. Once the preferred reaction route is identified then a separation method for the radioisotope needs to be developed. The separation methods need to be robust, reliable and cost effective in order to maintain a routine supply of the desired radioisotope.
Conclusions
Designing a PET radiopharmaceutical relies on careful consideration of a number of factors. They include the physical characteristics of the radioisotope, its chemistry and half life. For the former the critical aspects are the positron and gamma energies. A radioisotope with a low maximum positron energy is always preferred. The presence of any gammas contribute to radiation dose. High energy gammas require additional lead shielding and this significantly increases the cost of infrastructure. Gammas in the 350-700 keV range decrease PET image resolution and will require longer imaging times. The application of the radiopharmaceuticals in PET imaging will depend on the radioisotope's chemistry and biological half-life. The former requires the separation and radiolabelling to take place rapidly without extensive infrastructure and technical skills. Advances in the ability of cyclotrons to produce p, d and particles have substantially increased the range of metal PET radioisotopes that can be produced. However the yield and the cost effectiveness of the radioisotope production are ultimately dependent on the choice of nuclear reaction and the natural abundance of the target material used. Metal PET radioisotopes are ideal for labelling small molecules, peptides, proteins and particles via chelators and clearly have a role in the diagnosis of disease and risk assessment of new drugs. Of the 21 metal PET radioisotopes evaluated, 61 Cu and 64 Cu best meet the criteria for human use.
